A prospective single-arm clinical study on the role of Sintilimab (IBI308) combined with chemotherapy in neoadjuvant therapy of NSCLC in IB-IIIA stageA prospective single-arm clinical study on the role of Sintilimab (IBI308) combined with chemotherapy in neoadjuvant therapy of NSCLC in IB-IIIA stage
Latest Information Update: 01 Oct 2019
At a glance
- Drugs Sintilimab (Primary) ; Antineoplastics
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Oct 2019 New trial record